PSY123 - IDENTIFICATION OF THE TREATMENT ATTRIBUTES TO BE CONSIDERED IN SHARED DECISION MAKING FOR ANKYLOSING SPONDYLITIS PATIENTS: A SYSTEMATIC LITERATURE REVIEW

Abstract

Recently, the decision-making process for treatment in Ankylosing spondylitis (AS) patients becomes more complicated with biologics, and the need to incorporate patient perspective into treatment decision is continuously growing. This study aims to identify potentially considered attributes in decision-making process between AS patient and physician through the systematic literature review (SLR) Applying keywords and inclusion criteria such as “AS,” “decision,” “preference” and “attributes,” the PubMed and EMBASE were queried. Although the population of interest was AS patient, to capture and explore more varied attributes, we included AS related diseases as population: rheumatoid arthritis (RA), spondyloarthritis, and psoriatic arthritis. Attributes reported in included publications were extracted and summarized. The SLR was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 1,040 citations were searched, and 28 full-text publications of 25 studies met all inclusion criteria. All publications identified in the SLR were related to RA (n=25). There was no studies reporting attributes related to AS only. 20 studies were survey or interview. Among them, 15 studies involved patients as the study population. The most frequently used method to collect attributes was literature review (n=13). The most frequently reported attribute was safety (n=21) described as adverse event (n=17), infection (n=7) etc., followed by route of administration (n=20), frequency of administration(n=16), and efficacy (n=15). Economic considerations, patient characteristics, impact on daily life, the onset of action, medication burden, and fertility were also considered. Beyond efficacy, safety, route of administration and frequency of administration are the most common considerations in treatment decision-making especially when using biologics. These might be considered for AS patients in the real-world setting. Better understanding and considering these attributes may help physicians and patients reach out the shared-decision making and lead to higher patient satisfaction, improved adherence, and achievement of treatment goal.